A Nomogram based on Inflammatory Factors C-Reactive Protein and Fibrinogen to Predict the Prognostic Value in Patients with Resected Non-Small Cell Lung Cancer
机构:[1]State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China其他部门华南肿瘤学国家重点实验室中山大学肿瘤防治中心[2]Department of Clinical Laboratory, Sun Yat-sen University Cancer Center, Guangzhou, China临床科室临床研究部/药物临床试验机构中山大学肿瘤防治中心[3]Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, China临床科室临床研究部/药物临床试验机构中山大学肿瘤防治中心[4]Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China临床科室乳腺科中山大学肿瘤防治中心[5]School of Medical Laboratory Science, Guangdong Medical University, Dongguan, China[6]Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China其他科室检验科医学检验部中山大学附属第一医院
Purpose: This study aimed to develop an effective nomogram for predicting survival in surgically treated non-small cell lung cancer patients. Methods: We retrospectively evaluated 856 NSCLC in this study. Cox regression analyses were performed to identify significant prognostic factors for developing a nomogram to predict overall survival (OS). The discriminative ability was assessed with the concordance index (C-index). Results: On multivariate analysis of the 856 cohort, independent factors for survival were CRP, fibrinogen, tumor status, nodal status, distant metastasis and clinical stage, which were entered into the nomogram. The C-index of the established nomogram 0.720 (95% CI: 0.671-0.769) was higher than that of the seventh edition TNM staging system 0.689 (95% CI: 0.668-0.709) for predicting OS (P < 0.05). Compared with patients with low CRP levels (< 8.6 g/L) and low fibrinogen levels (< 3.7 g/L), patients with high CRP and fibrinogen levels had shorter OS. Subgroup analyses revealed that the nomogram was a favorable prognostic parameter in stage I-IV NSCLC (P < 0.05). Conclusion: A nomogram integrating CRP and fibrinogen, which could be convenient and feasible to obtain from the serum preoperatively, may assist in risk stratification for individual patient with resected NSCLC.
基金:
National Natural Science Foundation of China [81271902, 81472008]
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版:
大类|3 区医学
小类|4 区肿瘤学
第一作者:
第一作者机构:[1]State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China[2]Department of Clinical Laboratory, Sun Yat-sen University Cancer Center, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构:[1]State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China[2]Department of Clinical Laboratory, Sun Yat-sen University Cancer Center, Guangzhou, China[*1]Department of Clinical Laboratory, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, China.
推荐引用方式(GB/T 7714):
Qiuyao Zeng,Ning Xue,Danian Dai,et al.A Nomogram based on Inflammatory Factors C-Reactive Protein and Fibrinogen to Predict the Prognostic Value in Patients with Resected Non-Small Cell Lung Cancer[J].JOURNAL OF CANCER.2017,8(5):744-753.doi:10.7150/jca.17423.
APA:
Qiuyao Zeng,Ning Xue,Danian Dai,Shan Xing,Xia He...&Wanli Liu.(2017).A Nomogram based on Inflammatory Factors C-Reactive Protein and Fibrinogen to Predict the Prognostic Value in Patients with Resected Non-Small Cell Lung Cancer.JOURNAL OF CANCER,8,(5)
MLA:
Qiuyao Zeng,et al."A Nomogram based on Inflammatory Factors C-Reactive Protein and Fibrinogen to Predict the Prognostic Value in Patients with Resected Non-Small Cell Lung Cancer".JOURNAL OF CANCER 8..5(2017):744-753